MELATONIN

Brand name:

• Slenyto®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Insomnia

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (–)

Comment:

Item was considered by PBAC between its July 2021 and November 2021 meeting. No further action, please see MELATONIN link in Related medicines below.

Submission sponsor:

Aspen Pharmacare Australia Pty Ltd

Other PBAC consideration:

• MELATONIN
• MELATONIN

Submission received for::

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

14/12/2021

Lodgement of required documentation:

23/12/2021

Acceptance of complete documentation:

Not Accepted

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---